Corbus Return on Average Assets vs Return on Investment Analysis

CRBP Stock  USD 35.57  0.58  1.60%   
Trend analysis of Corbus Pharmaceuticals Holding balance sheet accounts such as Total Assets of 50.5 M, Short and Long Term Debt Total of 11.1 M or Other Current Liab of 5.9 M provides information on Corbus Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Corbus Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Corbus Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

About Corbus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Corbus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Corbus Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Corbus Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Corbus currently owns. An asset can also be divided into two categories, current and non-current.

Corbus Pharmaceuticals Balance Sheet Chart

Corbus Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Corbus Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Corbus Pharmaceuticals' Short Term Debt is relatively stable compared to the past year. As of 03/28/2024, Property Plant And Equipment Net is likely to grow to about 4.6 M, while Other Current Liabilities is likely to drop slightly above 5.9 M.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Corbus Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Corbus Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from Corbus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Corbus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
As of 03/28/2024, Selling General Administrative is likely to grow to about 14.6 B, while Issuance Of Capital Stock is likely to drop slightly above 231.9 K.

Corbus Pharmaceuticals fundamental ratios Correlations

-0.170.11-0.2-0.16-0.19-0.10.41-0.04-0.34-0.34-0.04-0.16-0.170.08-0.280.03-0.07-0.180.1-0.3-0.31-0.07-0.1-0.08-0.05
-0.170.770.20.640.840.67-0.44-0.690.520.760.690.980.770.820.630.80.821.00.210.760.180.870.780.790.53
0.110.770.160.670.470.760.06-0.880.310.390.750.730.820.890.410.950.880.750.480.41-0.310.670.770.80.73
-0.20.20.160.72-0.090.56-0.15-0.380.80.220.60.110.40.010.790.350.490.150.280.080.20.010.60.570.32
-0.160.640.670.720.230.89-0.3-0.740.850.590.860.540.770.510.880.760.920.60.460.460.030.450.880.890.73
-0.190.840.47-0.090.230.28-0.55-0.270.20.70.250.920.380.650.330.490.440.86-0.220.790.390.810.410.410.05
-0.10.670.760.560.890.28-0.24-0.670.770.560.750.580.670.720.810.720.940.620.280.49-0.260.360.960.960.69
0.41-0.440.06-0.15-0.3-0.55-0.24-0.14-0.54-0.89-0.06-0.47-0.07-0.13-0.5-0.01-0.24-0.450.39-0.56-0.64-0.34-0.24-0.23-0.05
-0.04-0.69-0.88-0.38-0.74-0.27-0.67-0.14-0.39-0.3-0.88-0.59-0.96-0.64-0.49-0.94-0.82-0.67-0.78-0.20.16-0.65-0.72-0.75-0.86
-0.340.520.310.80.850.20.77-0.54-0.390.650.680.420.50.320.940.40.720.480.10.480.250.190.80.780.47
-0.340.760.390.220.590.70.56-0.89-0.30.650.420.760.470.510.660.440.630.77-0.090.690.460.620.580.580.42
-0.040.690.750.60.860.250.75-0.06-0.880.680.420.570.860.590.690.840.880.650.60.330.070.510.830.840.76
-0.160.980.730.110.540.920.58-0.47-0.590.420.760.570.670.820.540.760.750.980.060.80.240.880.690.70.4
-0.170.770.820.40.770.380.67-0.07-0.960.50.470.860.670.60.580.910.830.750.730.340.00.720.720.740.86
0.080.820.890.010.510.650.72-0.13-0.640.320.510.590.820.60.370.770.810.80.080.58-0.240.60.760.780.51
-0.280.630.410.790.880.330.81-0.5-0.490.940.660.690.540.580.370.520.770.590.210.570.190.40.860.840.46
0.030.80.950.350.760.490.72-0.01-0.940.40.440.840.760.910.770.520.880.780.570.39-0.070.750.760.790.75
-0.070.820.880.490.920.440.94-0.24-0.820.720.630.880.750.830.810.770.880.780.40.56-0.10.590.950.970.76
-0.181.00.750.150.60.860.62-0.45-0.670.480.770.650.980.750.80.590.780.780.190.760.210.890.730.750.5
0.10.210.480.280.46-0.220.280.39-0.780.1-0.090.60.060.730.080.210.570.40.19-0.23-0.210.360.280.310.74
-0.30.760.410.080.460.790.49-0.56-0.20.480.690.330.80.340.580.570.390.560.76-0.230.220.590.580.570.05
-0.310.18-0.310.20.030.39-0.26-0.640.160.250.460.070.240.0-0.240.19-0.07-0.10.21-0.210.220.29-0.12-0.14-0.19
-0.070.870.670.010.450.810.36-0.34-0.650.190.620.510.880.720.60.40.750.590.890.360.590.290.470.50.44
-0.10.780.770.60.880.410.96-0.24-0.720.80.580.830.690.720.760.860.760.950.730.280.58-0.120.471.00.63
-0.080.790.80.570.890.410.96-0.23-0.750.780.580.840.70.740.780.840.790.970.750.310.57-0.140.51.00.66
-0.050.530.730.320.730.050.69-0.05-0.860.470.420.760.40.860.510.460.750.760.50.740.05-0.190.440.630.66
Click cells to compare fundamentals

Corbus Pharmaceuticals Account Relationship Matchups

Corbus Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding2.1M2.6M4.1M4.2M4.3M2.9M
Total Assets49.1M102.3M107.7M66.3M28.3M50.5M
Short Long Term Debt Total9.4M26.8M26.6M25.1M20.9M11.1M
Other Current Liab22.4M797K133.7K6.0M11.1M5.9M
Total Current Liabilities34.9M31.9M17.0M12.6M31.9M16.9M
Total Stockholder Equity6.2M45.3M69.1M33.0M(6.9M)(6.6M)
Net Debt(22.3M)(58.6M)1.6M8.1M7.0M7.3M
Retained Earnings(192.8M)(304.1M)(349.7M)(392.1M)(436.7M)(414.8M)
Accounts Payable11.1M7.4M1.8M2.2M3.2M4.0M
Cash31.7M85.4M25.0M17.0M13.9M13.2M
Cash And Short Term Investments31.7M85.4M97.6M59.2M21.1M20.0M
Common Stock Total Equity5.6K5.7K6.5K9.9K11.4K11.9K
Liabilities And Stockholders Equity49.1M102.3M107.7M66.3M28.3M50.5M
Non Current Liabilities Total8.1M25.1M21.6M20.7M3.3M3.1M
Other Current Assets6.4M3.7M2.4M791.6K2.4M2.3M
Other Stockholder Equity199.0M349.4M418.9M425.2M429.8M216.4M
Total Liab43.0M57.0M38.6M33.3M35.2M25.1M
Total Current Assets38.2M92.1M100.2M60.2M23.5M46.1M
Short Term Debt1.3M1.7M5.0M4.4M17.6M18.5M
Common Stock6.5K9.9K12.5K417.0442.0419.9
Net Tangible Assets6.2M45.3M69.1M33.0M37.9M32.1M
Property Plant And Equipment Net10.9M9.3M7.0M5.5M4.0M4.6M
Non Current Assets Total11.0M10.2M7.5M6.1M4.7M4.9M
Non Currrent Assets Other85.0K234.0K46.4K155.3K212.8K223.4K
Retained Earnings Total Equity(65.7M)(121.4M)(192.8M)(304.1M)(273.7M)(260.0M)
Capital Surpluse123.5M148.9M199.0M349.4M401.8M421.9M
Property Plant And Equipment Gross10.9M9.3M7.0M5.5M7.6M5.0M
Short Long Term Debt752.7K710.2K3.9M3.1M16.2M17.0M
Accumulated Other Comprehensive Income(666.6K)(1.4M)(62.4K)(126.1K)(1.6K)(1.6K)
Property Plant Equipment5.1M9.3M7.0M5.5M6.3M3.9M

Pair Trading with Corbus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Corbus Stock

  0.83EQ Equillium Financial Report 9th of May 2024 PairCorr

Moving against Corbus Stock

  0.88KA Kineta Inc Report 29th of March 2024 PairCorr
  0.86MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.85MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.82VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.78TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.
The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Corbus Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Corbus Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Corbus Pharmaceuticals Holding Stock. Highlighted below are key reports to facilitate an investment decision about Corbus Pharmaceuticals Holding Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Corbus Pharmaceuticals information on this page should be used as a complementary analysis to other Corbus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Corbus Stock analysis

When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Money Managers
Screen money managers from public funds and ETFs managed around the world
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Is Corbus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corbus Pharmaceuticals. If investors know Corbus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corbus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(10.31)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.60)
Return On Equity
(3.42)
The market value of Corbus Pharmaceuticals is measured differently than its book value, which is the value of Corbus that is recorded on the company's balance sheet. Investors also form their own opinion of Corbus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corbus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corbus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corbus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corbus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corbus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corbus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.